Patents by Inventor Margot Brickelmaier
Margot Brickelmaier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160250340Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: April 18, 2016Publication date: September 1, 2016Applicant: BIOGEN MA INC.Inventors: Blake PEPINSKY, Laura RUNKEL, Margot BRICKELMAIER, Adrian WHITTY, Paula HOCHMAN
-
Publication number: 20160151390Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immuno-compromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: December 3, 2015Publication date: June 2, 2016Applicant: Biogen MA Inc.Inventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Patent number: 9314534Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: GrantFiled: August 16, 2012Date of Patent: April 19, 2016Assignee: Biogen MA Inc.Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Patent number: 9233107Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: GrantFiled: September 13, 2008Date of Patent: January 12, 2016Assignee: Biogen MA Inc.Inventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Publication number: 20150011732Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: August 16, 2012Publication date: January 8, 2015Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Publication number: 20140199291Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: September 13, 2008Publication date: July 17, 2014Applicant: Biogen Idec MA IncInventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Publication number: 20130183289Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: September 13, 2008Publication date: July 18, 2013Applicant: Biogen Idec MA IncInventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Publication number: 20090286958Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: ApplicationFiled: March 18, 2009Publication date: November 19, 2009Applicant: Biogen Idec MA Inc.Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
-
Patent number: 7527946Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: GrantFiled: June 15, 2004Date of Patent: May 5, 2009Assignee: Biogen Idec MA Inc.,Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
-
Publication number: 20090104150Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: March 20, 2008Publication date: April 23, 2009Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Patent number: 7446173Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: GrantFiled: March 16, 2004Date of Patent: November 4, 2008Assignee: Biogen Idec MA Inc.Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Publication number: 20070098688Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: March 16, 2004Publication date: May 3, 2007Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Patent number: 6962978Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: GrantFiled: April 11, 2001Date of Patent: November 8, 2005Assignee: Biogen, Inc.Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Publication number: 20050214253Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: ApplicationFiled: June 15, 2004Publication date: September 29, 2005Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
-
Patent number: 6800735Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: GrantFiled: April 11, 2001Date of Patent: October 5, 2004Assignee: Biogen, Inc.Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
-
Publication number: 20030021765Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: April 11, 2001Publication date: January 30, 2003Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
-
Publication number: 20020155547Abstract: A fusion polypeptide is described having the amino acid sequence X—Y—Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.Type: ApplicationFiled: April 11, 2001Publication date: October 24, 2002Inventors: Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman